The company said its Q3 2025 revenue rose 13.1% from a year earlier to $2,816 million, reported diluted EPS was $2.16 and adjusted diluted EPS was $2.60. The company said the 13.1% revenue increase included 6.8% organic growth.

1. 01

   The company said its Q3 2025 revenue rose 13.1% from a year earlier to $2,816 million, reported diluted EPS was $2.16 and adjusted diluted EPS was $2.60. The company said the 13.1% revenue increase included 6.8% organic growth.

2. 02

   The company gave full-year 2025 outlook for revenue of $10.96 billion to $11.00 billion and adjusted diluted EPS of $9.76 to $9.84. Its prior outlook was $10.80 billion to $10.92 billion for revenue and $9.63 to $9.83 for adjusted diluted EPS. Reported diluted EPS outlook is now $8.58 to $8.66, compared with the prior $8.60 to $8.80.

3. 03

   Quest Diagnostics said operating cash flow for the 9 months ended 2025 was $1,421 million, compared with $870 million a year earlier. Over the same period, it repaid $1,011 million of debt, repurchased shares for $150 million and paid dividends of $263 million.

4. 04

   The company said it agreed with Corewell Health to form a lab services joint venture in Michigan. It also said annual Co-Lab Solutions revenue is expected to reach about $1 billion next year as services expand across 21 Corewell hospitals.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.